Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

NCT06338644 is registered in ClinicalTrials.gov with Helwan University as lead sponsor.

NCT NCT06338644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06338644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.
Lead sponsor
Helwan University
Phase
Observational
Overall status
Not yet recruiting
Start date
July 1, 2024
Completion date
September 1, 2026
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-receptor-positive breast cancer, human epidermal growth factor 2 negative carcinoma of breast, metastatic breast cancer